Miglustat-d9
Miglustat-d9 is the deuterium labeled Miglustat. Miglustat (N-Butyldeoxynojirimycin) is an inhibitor of glucosylceramide synthase, primarily to treat Type I Gaucher disease (GD1) [1][2].
Product Specifications
CAS Number
1883545-56-9
Product Name Alternative
N-Butyldeoxynojirimycin-d9; NB-DNJ-d9; OGT 918-d9
UNSPSC
12352005
Target
Glucosylceramide Synthase (GCS) ; Isotope-Labeled Compounds
Type
Isotope-Labeled Compounds
Related Pathways
Neuronal Signaling; Others
Field of Research
Neurological Disease
Solubility
10 mM in DMSO
Smiles
[2H]C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])N1[C@@H]([C@H]([C@@H]([C@H](C1)O)O)O)CO
Molecular Formula
C10H12D9NO4
Molecular Weight
228.33
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Abian, O., et al., Therapeutic strategies for Gaucher disease: miglustat (NB-DNJ) as a pharmacological chaperone for glucocerebrosidase and the different thermostability of velaglucerase alfa and imiglucerase. Mol Pharm, 2011. 8 (6) : p. 2390-7.|[3]van Giersbergen, P.L. and J. Dingemanse, Influence of food intake on the pharmacokinetics of miglustat, an inhibitor of glucosylceramide synthase. J Clin Pharmacol, 2007. 47 (10) : p. 1277-82.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog